Robert K. Zeldin, M.D.
Dr. Robert Zeldin has served as Chief Medical Officer of MeiraGTx since August 2020. A clinical immunologist by training, Dr. Zeldin brings over two decades of clinical, regulatory, and industry experience to MeiraGTx. Previously, Dr. Zeldin was CMO of Acceleron Pharma where he was instrumental in the preparation of the biologics license application for luspatercept which has been approved in the U.S. and Europe for the treatment of anemia associated with myelodysplastic syndromes and anemia associated with beta thalassemia, as well as CMO of Immunovant. Prior to Acceleron, he was CMO of Belgium-based Ablynx NV, where he directed the Phase 3 development program and regulatory filings of caplacizumab, which has been approved for the treatment of thrombotic thrombocytopenic purpura in the U.S. and Europe. Dr. Zeldin also served as Senior Vice President and Head of Global Clinical Development at Stallergenes SA and Vice President and U.S. Medical Franchise Head – Respiratory and Dermatology at Novartis Pharmaceuticals. Earlier in his career, Dr. Zeldin spent seven years at Merck in increasingly strategic roles in worldwide regulatory affairs and clinical development. Prior to his work in industry, Dr. Zeldin served as a Medical Officer at the U.S. Food & Drug Administration’s Center for Biologics Evaluation and Research. He also spent several years in clinical practice.
Dr. Zeldin holds a B.A. with honors from the Johns Hopkins University and a M.D. from Tufts University School of Medicine. His postdoctoral training included Residency in Internal Medicine at the University Health Center of Pittsburgh and Fellowship in Allergy and Clinical Immunology at the Johns Hopkins University School of Medicine.